Is a recipient of a primary or secondary allograft kidney
Is at least 4 weeks posttransplant and not more than 52 weeks posttransplant at the time of enrollment (Day 1) and is being managed per local standard of care
Has stable kidney function posttransplant
Has undetectable CMV deoxyribonucleic acid (DNA) from a plasma or whole blood sample collected within 14 days prior to enrollment
Must be able to take (as assessed by the investigator) letermovir tablets or oral pellets by mouth, or via gastrostomy or nasogastric tube (oral pellets only)
Does not have a condition that may interfere with the absorption of oral medication (e.g., vomiting, diarrhea, or a malabsorptive condition) from the day of enrollment (Day 1) until the intensive pharmacokinetics (IPK) sampling is completed
Weighs ≥2.5 and \<40 kg at enrollment (Day 1)
You may not be if
Has CMV disease or suspected CMV disease between screening and enrollment
Is on dialysis or plasmapheresis at the time of enrollment
Has evidence of CMV viremia at any time from screening until the time of enrollment
Has Child-Pugh B or C hepatic insufficiency within 14 days before enrollment
Is a multi-organ transplant recipient (e.g., kidney-pancreas)
Has any uncontrolled infection on the day of enrollment
Requires mechanical ventilation, or is hemodynamically unstable, at the time of enrollment
Has received or is receiving protocol-specified prohibited medications
Clareo Health | A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)
